anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Exercise is beneficial for people with Multiple Sclerosis (pwMS). However, exercise options for those with moderate to high levels of disability are limited. Cycling, delivered with an Active Passive Trainer (APT) is one exercise option often offered within rehabilitation/exercise settings and many pwMS buy APTs for home use. Anecdotally, pwMS report they feel better and their spasticity reduces after APT cycling, however there is a lack of evidence to support this.

30 pwMS will be recruited from the Physical Disability Rehabilitation Unit at the Queen Elizabeth University Hospital, Glasgow, and randomised to APT + usual care or usual care only. Those in the APT group will receive 30 minutes of APT (2 mins passive warm up, 26 mins active cycling and 2 mins passive cool down), five days per week for 4 weeks. Outcome measures will be cardiovascular fitness measured using the oxygen uptake efficiency slope (OUES), spasticity assessed by Modified Ashworth Scale (MAS) and the Multiple Sclerosis Spasticity Scale (MSSS-88), function assessed by the Functional Independence Measure (FIM) and the Timed 25 foot walk test (T25FW), Quality of Life measured by MSQOL-54. Outcome measures will be assessed in both groups before and after the 4 week intervention period. Symmetry, distance cycled and power will be recorded following each cycling session in the intervention group.
A non-radioactive metallic stent is coated with a biodegradable or non-biodegradable thin coating of less than about 100 microns in thickness selected to avoid provoking any foreign body reaction. The coating contains a radioactive source of beta emitting properties for irradiation of tissue when the stent is implanted in a blood vessel treated by angioplasty, to inhibit proliferation of smooth muscle cells in response to trauma to the wall of the blood vessel from the angioplasty, and thereby prevent restenosis of the vessel. The stent coating incorporating the radioactive source constitutes a first layer atop the surface of the stent, and the coating further includes a second layer incorporating an anti-coagulant substance to inhibit early thrombus formation of the stent. The second layer is adhered to and atop the first layer. The composite layer of the coating has a thickness of less than about 100 microns. The activity level of the radioactive source is approximately one microcurie.
This is a quadruple blinded randomized controlled trial. Therefore, the allocation of participants to either placebo or metformin is unknown by the participant, research personnel, investigator, or blinded statistician. A total of 200 participants will be randomized over the course of 3 years. Study drug is administered to participants after all inclusion and no exclusion criteria is confirmed, informed consent is completed, and they are randomized. Study drug is continued throughout for 6 months following randomization. Participants are prospectively observed and monitored for 12 months after randomization. The patients' involvement (study visits/study phone calls) will last 12 months. Then, for 5 years, the study team will do a medical chart review as outlined in the ICF and protocol. All main study endpoints are within the 12-month time point. Secondary endpoints including MACE and MALE - major adverse cardiac and major adverse limb events - are time to event end points which can continue beyond the 12-month study time frame and will inform not only the effect of metformin on IC but also the natural history of IC among patients enrolled in the study.
Methods and compositions for inhibiting and/or inactivating nucleases by employing nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors. The anti-nuclease antibodies of the present invention may be a polyclonal or monoclonal antibodies, and may be anti-ribonuclease antibodies, anti-deoxyribonuclease antibodies, or antibodies to non-specific nucleases. A preferred embodiment comprises at least two nuclease inhibitors, and is referred to as a nuclease inhibitor cocktail. In some specific embodiments, the invention concerns methods of performing in vitro translation comprising obtaining a first nuclease inhibitor, which inhibitor is further defined as an anti-nuclease antibody, and placing the anti-nuclease antibody in an in vitro translation reaction. In many cases, the in vitro translation reaction comprises at least one nuclease, which may be a ribonuclease, a deoxyribonuclease, or a nonspecific nuclease. The invention also relates to kits for the performance of various microbiological procedures, which kits comprise the nuclease inhibitors described herein.
Participants received 4 group sessions, session 1 focused on positive affect psychoeducation, session 2 on mindfulness, 3 on savoring and 4 on gratitude. Once completing the group sessions participants received text messages for 1 month before tapering off.
Proton radiation therapy daily (Monday through Friday) for 4-8 weeks. This is a single arm study.
Endpoint implementation of reactions initiated by ischemia is the mitochondrial transition pore permeability. Mitochondria pores opening results in a release of factors triggering apoptosis. primarily the cytochrome С Inhibition of the pores opening protects ischemic damage of the cells. The key enzyme regulating the mitochondrial permeability transition pore is glycogen synthase-kinase 3b (GSK-3b): the phosphorylation of the enzyme inactivates the enzyme and prevents pore opening. We have shown in previous study that preconditioning with sevoflurane increases the content of the phosphorylated form of 6SK-3b and protects the mitochondria of neurons in rats brain during ischemia/reperfusion. Aim of studi is to determine content of the phosphorylated GS K-3b in neurons of rat brain in the model of total ischemia/reperfusion influenced by: 1 MAC desflurane vs control group; 1 MAC desflurane vs 1 MAC sevoflurane and 1 MAC desflurane vs training ischemia.
VVX001 is a recombinant fusion Protein composed of PreS from the large surface antigen of HBV and Peptides derived from the grass pollen allergen Phl p 5. In a previous trial in allergic but otherwise healthy subjects the product has been shown to elicit a potent IgG response to the epitope of PreS1, which is responsible for binding to the cellular receptor NTCP. These antibodies prevent infection with HBV in a cell culture model. The present study will evaluate if such an immune response can also be achieved in four different patient populations: 1) vaccine naive subjects; 2) subjects having failed to seroconvert upon vaccination with a licensed HBV vaccine; 3) patients who are chronically infected with HBV, but are classified as inactive carriers; 4) patients with active chronic HBV infection who are HbEAg negative and chronically treated with nucleo(t)side (NUC) antiviral drugs. All subjects will receive 5 s.c. injections of VVX001, the time course of antibody response to PreS1 will be monitored in all of them. In cohort 4) NUC treatment will be withdrawn at different timepoints during the study and the effect of treatment with VVX001 on hepatitis B disease Parameters will be monitored. Subjects will be followed for 6 months after the of treatment for Evaluation of a long-term effect.
An amount of Investigational Product will be topically applied to malar and forehead areas (after cleansing the face) on one randomized side of the participant's face by a qualified technician to perform the assessment of a 12-hour kinetics. After the evaluations the product will be removed.
The invention provides algin nitrate and a preparation method and application thereof. The algin nitrate provided by the invention comprises a compound shown in a formula (I), wherein in the formula (I), R  1  Is H or metal ion; r is R  2  Is H or NO  2  The method comprises the steps of carrying out a first treatment on the surface of the m and g are natural numbers, m+g is more than or equal to 25, and m/(m+g) is more than or equal to 0.2 and less than or equal to 1. The algin nitrate provided by the invention has good stability, safety and biocompatibility. The alginate nitrate provided by the invention can stably release nitric oxide in vitro and permeate the skin after being catalyzed, and the alginate nitrate prototype cannot permeate the skin. The algin nitrate provided by the invention can be applied to the surface of skin, and can expand subcutaneous capillaries after catalyzing nitric oxide release, so as to improve skin microcirculation. The algin nitrate provided by the invention can be used in related products for improving skin microcirculation, and does not generate toxic or side effect.
A tattoo ink formulation that is operable to provide a long persistence of phosphorescence subsequent dermal presentation. The formulation of the present invention includes strontium aluminate as a pigment base wherein the pigment based further includes at least one dopant. In the preferred embodiment of the present invention either europium or dysprosium as employed as dopants wherein the dopants result in the pigment base having a behavior of a photoluminescent phosphor with a long persistence of phosphorescence. The tattoo ink formulation further includes glycerin wherein the glycerin comprises between sixty-five to sixty seven percent of the total volume of the formulation. The formulation further includes approximately one to two percent of ethanol. In a preferred embodiment of the present invention the particle size of the pigment base is one micron and is dermally presented with round shader tattoo needles.
Total knee arthroplasty (TKA) is a cost beneficial surgery shown to improve pain, function and quality of life in patients with osteoarthritis. In 2015, 6093 patients received primary TKA in Norway. Despite the procedure´s general success, 20% of patients report persistent postoperative pain and/or dissatisfaction with the surgical outcome. Efforts to further improve the procedure have raised considerable debate regarding the role and management of the posterior cruciate ligament (PCL). Prostheses for TKA have evolved into designs that either preserve or sacrifice the PCL. In patients with a functional PCL, the decision of which design is selected depends largely on the favor and training of the surgeon. To further improve TKA patient outcomes, a better understanding of the role of these differing PCL treatments is needed. Thus, the aim of this study is to determine whether patients' perceived outcome, implant stability and clinical outcome differ between 3 TKA implant designs (2 PCL-sacrificing and 1 PCL-retaining). We will conduct a 3-arm randomized controlled prospective trial with 5-year follow-up. This study will have impact on clinical practice by addressing the lack of evidence supporting use of these different types of implants.
Metabolic dysfunction-associated steatohepatitis (MASH) is a common but frequently unrecognized complication of obesity and type 2 diabetes. The association between these conditions is multifaceted and involves complex interactions between metabolic, inflammatory, and genetic factors. Here we assess the underlying structural and molecular processes focusing on the immunological phase of MASH in the nonobese inflammation and fibrosis (NIF) mouse model and compare it to the human disease as well as other murine models. Histopathology together with synchrotron-radiation-based x-ray micro-computed tomography (SRµCT) was used to investigate structural changes within the hepatic sinusoids network in the NIF mouse in comparison to patients with different severities of MASH. A time-course, bulk RNA-sequencing analysis of liver tissue from NIF mice was performed to identify the dynamics of key processes associated with the pathogenesis. Transcriptomics profiling of the NIF mouse revealed a gradual transition from an initially reactive inflammatory response to a regenerative, pro-fibrotic inflammatory response suggesting new avenues for treatment strategies that focus on immunological targets. Despite the lack of metabolic stress induced liver phenotype, a large similarity between the NIF mouse and the immunological phase of human MASH was detected. The translational value was further supported by the comparative analyses with MASH patients and additional animal models. Finally, the impact of diets known to induce metabolic stress, was explored in the NIF mouse. An obesogenic diet was found to induce key physiological, metabolic, and histologic changes akin to those observed in human MASH.
Digital precision medicine is gaining increasing importance in rhythmology, especially in the treatment of cardiac arrhythmias. This trend is driven by the advancing digitization in healthcare and the availability of large amounts of data from various sources such as electrocardiograms (ECGs), implants like pacemakers and implantable cardioverter-defibrillators (ICDs), as well as wearables like smartwatches and fitness trackers. Through the analysis of this data, physicians can develop more precise and individualized diagnoses and treatment strategies for patients with cardiac arrhythmias. For example, subtle changes in ECGs can be identified, indicating potentially dangerous arrhythmias. Genetic analyses and resulting large datasets also play an increasingly significant role, especially in hereditary ion channel disorders such as long QT syndrome (LQTS) and Brugada syndrome (BrS), as well as in lone atrial fibrillation (AF). Precision medicine enables the development of individualized treatment approaches tailored to the specific needs and risk factors of each patient. This can help improve screening strategies, reduce adverse events, and ultimately enhance the quality of life for patients. Technological advancements such as big data, artificial intelligence, machine learning, and predictive analytics play a crucial role in predicting the risk of arrhythmias and sudden cardiac death. These concepts enable more precise and personalized predictions and support physicians in the treatment and monitoring of their patients.
BACKGROUND: Although post-traumatic stress disorder (PTSD) and depression screening are recommended for traumatic injury patients, routine screening is still uncommon. Salivary inflammatory biomarkers have biological plausibility and potential feasibility and acceptability for screening. This study tested prospective associations between several salivary inflammatory biomarkers (proinflammatory cytokines interleukin-1β, interleukin-6, tumor necrosis factor-α; and C-reactive protein), collected during hospitalization and PTSD and depressive symptoms at 5-month follow-up.
METHODS: Adult traumatic injury patients (N = 696) at a major urban Level 1 trauma center provided salivary samples and completed PTSD and depressive symptom measures during days 0-13 of inpatient hospitalization. At 5-month follow-up, 368 patients (77 % male, 23 % female) completed the Clinician-Administered PTSD Scale for DSM-IV and the Self-rated Inventory of Depressive Symptomatology. Analyses focused on a latent inflammatory cytokine factor and C-reactive protein at baseline predicting 5-month PTSD and depression symptom outcomes and included baseline symptom levels as covariates.
RESULTS: A latent factor representing proinflammatory cytokines was not related to 5-month PTSD or depressive symptom severity. Higher salivary CRP was related to greater PTSD symptom severity (β = .10, p = .03) at 5-month follow-up and more severity in the following depressive symptoms: changes in weight and appetite, bodily complaints, and constipation/diarrhea (β's from .14 to .16, p's from .004 -.03).
CONCLUSION: In a primarily Latine and Black trauma patient sample, salivary CRP measured after traumatic injury was related to greater PTSD symptom severity and severity in several depressive symptom clusters. Our preliminary findings suggest that salivary or systemic CRP may be useful to include in models predicting post-trauma psychopathology.
<P>PROBLEM TO BE SOLVED: To provide a method extending to both of the fields of medical science and engineering wherein cancer cells are suppressed using an LED (light emitting diode) and a rare sugar.  <P>SOLUTION: The method for suppressing the proliferation of the cancer cells by irradiating the cancer cells with a blue or green LED in existence of the rare sugar is described. The rare sugar is preferably D-allose. After making the rare sugar act on the cancer cells, the cancer cells are irradiated with the LED. The cancer cells are liver cancer cells (HepG2 cells). The cancer cells are irradiated with the blue or green LED. The cancer cells which are liver cancer cells (HepG2 cells) are nearly entirely extinguished by irradiating them with the green LED.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Any patient alternatively receive both remifentanil and isotonic saline (placebo)infusion. The order of infusion is randomized. An interval of 30 minutes is planned between the two infusions.
PURPOSE: To obtain a zirconium based Mo adsorbent having an excellent Mo- adsorbability and Tc-eluting property by constituting the adsorbent of a skeletal structure consisting mainly of repetition unit shown by a specific formula. CONSTITUTION: The Mo-absorbent for<99> Mo-<99m> Tc generator is composed of a skeletal structure consisting mainly of repetition unit shown by formulae I, II, III and IV, wherein X is halogen or a 1 to 6 C alkoxy group and at least 10% of X is halogen; R is 1 to 6 C alkylene or polymethylene, or a carbon chain with an unsaturated bond. The branched structure is controlled by the bonding at any one of the unit of repetition and the content of the repetition unit. The adsorbent is water-insoluble, adsorbs only Mo from an aqueous solution containing Mo, and is capable of eluting<99m> Tc generated from<99> Mo, a radioactive isotope. Thus the Mo adsorbent is used for the preparation of a practical generator, using<99> Mo obtained from a natural Mo.  The adsorbent is obtained by thermally treating a precursor which is available by a chemical reaction between zirconium halide or halogenated zirconium oxide and alcohol.
The present invention discloses a new application of the isoflavone of soybean. According to the research of an inventor of the present invention, the isoflavone of the soybean has effect on resisting ionization radiation, and the isoflavone of the soybean can be widely used for preparing medicine and foods resisting the ionization radiation. The medicine or the foods can be used for preventing before ionization radiation contact or can be used for the adjuvant treatment of the damages of a machine body caused by the radiation after the ionization radiation contact, and effective dose is from 1 to 20 g of isoflavone of the soybean/person. day. The present invention can be widely used for the clinical symptoms of fatigue asthenia, dizziness headache, decreased food appetite, digestive functional disturbance, descending immunity, etc. of acute radiation patients, tumor radiation treatment patients and radioactive substance contact persons because of the influence of the ionization radiation.
The investigators will collect outcomes for 100 Veterans treated with usual care rehabilitation after total knee arthroplasty. Data will be collected at all participating clinical locations. Data collection for these Veterans will precede data collection for the intervention cohort.
Cardiovascular complications, such as myocardial infarction (MI) and stroke are common in the perioperative period of noncardiac surgeries. To the moment there are no safe and effective interventions to reduce vascular events in this scenario. Data from observational studies and small-sized randomized controlled trials (RCTs) have shown promising results in terms of risk reduction. In addition, experimental data have indicated that statins have acute anti-inflammatory properties, which promote the stabilization of atherosclerotic lesions and, therefore, might reduce the risk of MI, even in the short term. This study was designed to explore the effects of atorvastatin, as compared with placebo, on the 30-day risk of a composite of death, nonfatal Myocardial Injury after Noncardiac Surgery (MINS), or stroke among patients who undergo noncardiac surgery.

The study was conducted in accordance with the prespecified protocol and reached successful enrollment rates when, by the end of 2014 the steering committee was invited to join an international initiative and participate in a much larger clinical trial to investigate this relevant question. Due to this outstanding possibility, the steering committee decided to redesign the study which is now formatted as an exploratory trial. As described, the study was completed with the inclusion of 648 participants in June, 2015.
PURPOSE: To selectively and efficiently adsorption-remove saccharified protein from a body liquid by using a copolymer comprising a monomer unit having dihydroxyboryl group and a monomer unit having anionic functional groups to constitute an adsorbent. CONSTITUTION: This adsorbent for saccharified protein consists of a copolymer comprising a monomer unit having dihydroxyboryl groups and a monomer unit having anionic functional groups. This adsorbent for saccharified protein is brought into contact with a body liquid to adsorption-remove saccharified protein from the body liquid. The monomer unit having dihydroxyboryl groups [(CHO)2 B-] is not specified as far as it has dihydroxyboryl groups. Also, the monomer unit having anionic functional groups is not specified as far as it has anionic functional groups. As for the monomer source material having dihydroxyboryl groups, p-styreneboronic acid is preferable, and acrylic acid is preferable for the monomer source material having anionic functional groups.
BACKGROUND: The code ST-segment elevation myocardial infarction (STEMI) program is an operational standard of integrated service for STEMI patients carried out by Dr. Cipto Mangunkusumo Hospital. The emerging coronavirus disease 2019 (COVID-19) outbreak brought about many changes in the management of healthcare services, including the code STEMI program. This study aimed to evaluate the healthcare service quality of the Code STEMI program during the COVID-19 pandemic based on the Donabedian concept.  Methods: This was a mixed-methods study using quantitative and qualitative analyses. It was conducted at the Dr. Cipto Mangunkusumo Hospital, a national referral hospital in Indonesia. We compared the data of each patient, including response time, clinical outcomes, length of stay, and cost, from two years between 2018-2020 and 2020-2022 as the pre-COVID-19 code STEMI and COVID-19 Code STEMI periods, respectively. Interviews were conducted to determine the quality of services from the perspectives of stakeholders.
RESULTS: A total of 195 patients participated in the study: 120 patients in pre-COVID-19 code STEMI and 75 patients in COVID-19 code STEMI. Our results showed that there was a significant increase in patient's length of stay during the COVID-19 pandemic (4 days vs. 6 days, p < 0.001). Meanwhile, MACE (13% vs. 11%, p = 0.581), the in-hospital mortality rate (8% vs. 5%, p = 0.706), door-to-wire crossing time (161 min vs. 173 min, p = 0.065), door-to-needle time (151 min vs. 143 min p = 0.953), and hospitalization cost (3,490 USD vs. 3,700 USD, p = 0.945) showed no significant changes. In terms of patient satisfaction, patients found code STEMI during COVID-19 to be responsive and excellent.
CONCLUSION: The implementation of the code STEMI program during the COVID-19 pandemic revealed that modified pathways were required because of the COVID-19 screening process. According to the Donabedian model, during the pandemic, the code STEMI program's healthcare service quality decreased because of a reduction in efficacy, effectiveness, efficiency, and optimality. Despite these limitations attributed to the pandemic, the code STEMI program was able to provide good services for STEMI patients.